Alembic Pharmaceuticals Q2FY26 Results – The API Artist That Refuses To Expire
1. At a Glance
Alembic Pharmaceuticals just dropped its Q2FY26 results like a pharma bomb — revenue ₹1,910 crore (up 16% YoY), PAT ₹185 crore (up 20%), and EBITDA ₹325 crore. The stock, sitting pretty at ₹960, looks less like a prescription and more like a lesson in slow but consistent dosage. With a market cap of ₹18,870 crore, P/E of 29.7x, ROE at 11.4%, and a healthy dividend yield of 1.14%, Alembic is the kind of stock your cautious uncle brags about holding since the 90s — but can’t remember when it actually moved.
Over the last year, the company’s share price has had its own dosage pattern — up 13.5% over 3 years, down 14.5% over the last year, and barely a pulse in 3 months (+1.31%). But underneath that calm, Q2FY26 numbers whisper that the patient may finally be recovering. With a consistent rise in quarterly profits, expanding margins, and a strong generics pipeline, Alembic is trying to regain its pre-COVID swagger.
And oh — they’ve gone shopping again! The company acquired Utility Therapeutics (UK) for USD 25 million, adding some much-needed R&D muscle in the antibiotics and UTI segment. The Amin family might just be preparing to write a new prescription for growth.
2. Introduction
In a pharma market that behaves more dramatically than a daily soap — one quarter you’re the hero curing the world, next quarter you’re struggling with USFDA mood swings — Alembic Pharmaceuticals stands out like that nerdy topper who never really flunks, but also never becomes the rockstar.
Founded in the 1900s but acting like a Gen-Z lab genius, Alembic has built its empire on generics — the bread and butter of Indian pharma. It’s not Sun Pharma-level glamorous or Divi’s Lab-level rich, but it quietly runs the show in formulations and APIs, flexing its chemistry muscles across India, the US, and 70 other markets.
This quarter’s results bring back the swagger that’s been missing since the post-2021 slowdown. Double-digit growth across India and international markets, expanding operating margins, and a visible rebound in US formulations — it’s like watching an old Bollywood actor make a surprise comeback with better direction and less overacting.
The Amin family (of Baroda fame) still holds ~70% stake, with patriarch Chirayu Amin — who’s seen it all, from antibiotics to IPL ownership — ensuring Alembic remains both a pharmacy and a family affair.
3. Business Model – WTF Do They Even Do?
Alembic’s business is divided into two main painkillers: Formulations (83%) and Active Pharmaceutical Ingredients (APIs) (17%).
The Formulations business is the rockstar. Think tablets, capsules, injectables, ophthalmic products, oncology meds — basically anything your doctor can scribble illegibly.
India Formulation (35% of FY25 revenue): Focused on branded generics, Alembic ranks #20 in the Indian pharma market with a 1.4% share. They cater to everything from anti-infectives to gynecology, with 204 brands lighting up chemist shelves. The acute therapy segment might be tapering off, but specialty and veterinary wings are flexing new muscles.
US Formulation (29%): Their American dream involves 163 commercialized products and 266 ANDA filings, out of which 46 are still pending with the ever-grumpy USFDA. The US business grew 24% between FY23 and FY25, launching 16 new products in FY25 alone.
Ex-US Formulation (19%): Europe, Canada, Brazil, Australia, and South Africa – Alembic’s “pharma tourism” business. Growth here is 46% in two years, thanks to smart partnerships and 40 product launches planned for FY26.
Then there’s the API business (17%), the backbone that supplies both in-house formulations and third-party clients. With 194 APIs manufactured, Alembic is not just making drugs – it’s selling the recipes too. The division took a 3% knock due to pricing pressure, but expansion plans (including peptide blocks) suggest it’s ready to bounce back.
In short: if pharma were cricket, Alembic is the dependable No. 4 batsman – doesn’t hit sixes, but keeps the scoreboard ticking.
